الدكتورة ريم علي

باحث ما بعد الدكتوراه

البريد الإلكتروني

reaali@hbku.edu.qa

موقع المكتب

A140

الدكتورة ريم علي

باحث ما بعد الدكتوراه

المؤهلات العلمية

PhD in Oncology

MSc in Cancer Immunology and Biotechnology

الكيان

كلية العلوم الصحية والحيوية

السيرة الذاتية

Dr. Reem Ali is a postdoctoral researcher in the College of Health and Life Sciences at Hamad Bin Khalifa University. She received her PhD degree in Oncology from the University of Nottingham, United Kingdom.

Dr. Reem completed her first postdoctoral fellowship at the Wellcome Centre for Human Genetics, University of Oxford, United Kingdom, where she continued her work on identifying biomarkers for PARP inhibitor resistance in endometrial cancers. She also worked on targeting the base excision repair pathway in breast and ovarian cancers. She developed an interest in PARP inhibitors and studied the mechanisms of resistance to this first FDA-approved DNA repair inhibitor in humans.

PhD in Oncology

University of Nottingham, United Kingdom

2020

MSc in Cancer Immunology and Biotechnology

University of Nottingham, United Kingdom

2014

BSc Hons. in Biomedical Sciences

Nottingham Trent University, United Kingdom

2013

  • DNA damage and repair pathway
  • Precision medicine
  • PARP inhibitor

Postdoctoral Researcher

College of Health and Life Sciences, Hamad Bin Khalifa University

2022 - Present

Postdoctoral Fellow

Wellcome Centre for Human Genetics, University of Oxford, United Kingdom

2020 - 2022

Ali, R., Sulaiman, A. A., Memon, B., Pradhan, S., Algethami, M., Aouida, M., McKay, M., Madhusudan, S., Abdelalim, E. M., & Ramotar, D. (2023). Altered regulation of the glucose transporter GLUT3 in PRDX1 null cells caused hypersensitivity to arsenite. Cells, 12(2682).

Ali, R., Aouida, M., Alhaj Sulaiman, A., Madhusudan, S., & Ramotar, D. (2022). Can Cisplatin therapy be improved? Pathways that can be targeted. International Journal of Molecular Sciences, 23(13), 7241.

Sulaiman, A. A., Ali, R., & Ramotar, D. (2023). The histone H2B Arg95 residue efficiently recruits the transcription factor Spt16 to mediate Ste5 expression of the pheromone response pathway. Scientific Reports, 13(1), 10189.

Alblihy, A., Ali, R., Algethami, M., Shoqafi, A., Toss, M. S., Brownlie, J., Tatum, N. J., Hickson, I., Moran, P. O., Grabowska, A., Jeyapalan, J. N., Mongan, N. P., & Rakha, E. A., & Madhusudan, S. (2022). Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers. NPJ Precision Oncology, 6(1), 51.

Ali, R., Alblihy, A., Miligy, I., Alabdullah, M., Alsaleem, M., Toss, M., Abdel-Fatah, T., Moseley, T., Chan, S., Mongan, N., Narayan, S., Rakha, E., & Madhusudan, S. (2021). Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. Oncogene, 40, 2496–2508.

  • Poster prize award at the 6th EU-US Conference on Repair of Endogenous DNA damage- Udine, Italy, 2017
  • Oxford BRC post-doctoral research fellowship, Wellcome Trust for Human Genetics, Nuffield Department of Medicine